Anti-angiogenesis therapies, including vascular endothelial growth factor (VEGF) targeting agents, offer an alternative strategy to conventional chemotherapy; they inhibit the growth of new blood vessels, which blocks blood supply and thereby restricts tumor growth [7]. Here, VEGFA is linked to neoplasm.